Prohost Biotech – Exclusive Biotech Research

Exclusive Market Insight

& Scientific analysis

  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Menu
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us
  • Impacting News
  • News & Comments
  • Today’s Highlights
  • Trick or Trade
  • Prohost Letters
  • Login / Register
    • Login
    • Register
  • Contact Us

Latest Articlesddd

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

December 13, 2023 0
Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex  Pharmaceuticals (VRTX) announced positive results from …

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

December 11, 2023 0
Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr …

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

December 6, 2023 0
Novartis Approval Novartis (NVS) product Fabhalta (iptacopan) is a Factor B inhibitor that acts in the …

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

December 5, 2023 0
Roche in the NEWS From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results …

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

December 4, 2023 0
EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive …

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

December 2, 2023 0
Altimmune Positive Topline Results Altimmune (ALT) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity …

AbbVie Inc to Acquire ImmunoGen

November 30, 2023 0
AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. (ABBV) and ImmunoGen (IMGN) today announced …

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19  

November 28, 2023 0
Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders …

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

November 28, 2023 0
Immunovant Inc in the NEWS Immunovant, Inc. (IMVT) announced initial data from 600 mg MAD cohort …

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

November 22, 2023 0
Anavex Life Sciences Granted US Patent Anavex Life Sciences (AVXL) – a development-stage biopharmaceutical company announced that the United …

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.  

November 17, 2023 0
AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc (ABBV) announced detailed results published in The Lancet evaluating …

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

November 16, 2023 0
Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease …

About the FDA Approval of Eli Lilly’s Product Zepbound for Obesity   

November 10, 2023 0
FDA Approval of Eli Lilly Product Zepbound for Obesity On Wednesday, Nov. 8, 2023,  the U.S. …

Current News From Three Selected Biotech Firms

November 8, 2023 0
Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc (VRNA) announced that senior management …

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

November 6, 2023 0
CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics (CRSP) today announced preclinical data from the Company’s investigational …

More Good News for Neurocrine Biosciences

November 3, 2023 0
Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50  Yesterday, November 2, …

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

November 2, 2023 0
ImmunoGen in the NEWS Immunogen (IMGN) - a developer of  antibody-drug conjugates (ADCs) for cancer treatment …

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals

November 1, 2023 0
CRISPR Therapeutics and Vertex Pharmaceuticals NEWS CRISPR Therapeutics (CRSP) announced the completion of the U.S. Food …

Beam Therapeutics Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease

October 31, 2023 0
Beam Therapeutics in the NEWS Beam Therapeutics (BEAM) announced that Eli Lilly (LLY) has agreed to …
Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer’s Disease

October 26, 2023 0
Anavex Life Sciences NEWS Anavex Life Sciences (AVXL) reported a new peer reviewed publication in journal Neurobiology of Aging, titled “Early treatment with …

Posts pagination

Previous 1 … 9 10 11 12 13 14 15 … 77 Next

Search ProhostBiotech

Popular Links

Aerie Pharmaceuticals (AERI) Agenus (AGEN) Alnylam Pharmaceuticals (ALNY) Amgen (AMGN) Array BioPharma (ARRY) AstraZeneca Plc (AZN) Bellicum Pharmaceuticals Inc (BLCM) Bristol-Myers Squibb (BMY) Celgene (CELG) Celldex Therapeutics (CLDX) Cellectis (CLLS) Celyad (CYAD) Compugen (CGEN) CRISPR Therapeutics (CRSP) CytomX Therapeutics Inc (CTMX) Editas Medicine Inc (EDIT) Enanta Pharmaceuticals (ENTA) Exelixis (EXEL) Gilead Sciences (GILD) Halozyme Therapeutics (HALO) Illumina (ILMN) ImmunoGen (IMGN) Incyte (INCY) Innoviva (INVA) Intellia Therapeutics (NTLA) Ionis Pharmaceuticals Inc (IONS) Karyopharm Therapeutics Inc (KPTI) Merck (MRK) Moderna Inc (MRNA) Nektar Therapeutics (NKTR) Neurocrine Biosciences (NBIX) Novartis (NVS) Portola Pharmaceuticals Inc (PTLA) PTC Therapeutics (PTCT) Regeneron Pharmaceuticals (REGN) Regenxbio (RGNX) Rhythm Pharmaceuticals Inc (RYTM) Sangamo Therapeutics Inc (SGMO) Sarepta Therapeutics (SRPT) Seagen Inc (SGEN) Spark Therapeutics Theravance Biopharma (TBPH) Vertex Pharmaceuticals (VRTX) Xoma (XOMA)
  • Recent

ProhostBiotech Archive

Sign Up for Weekly Emails

Prohost Biotech – Exclusive Biotech Research Copyright © 2025.
© 2014 Prohost Biotech. All rights reserved.

Privacy Policy | Cancellation Policy | Forward Looking Statement

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.